A spokesperson for the Office of the Inspector General, who was involved in the case, commented, “Pharmaceutical companies that ignore rules designed to protect patients will be held accountable. Patients must be able to trust that decisions made by their doctors are based on unbiased professional judgment and not personal gain.”
The U.S. Attorney has especially thanked Bergman for being brave enough to come forward and assist the government in ending the alleged misconduct by a known violator. He emphasized the importance of whistleblowers to shine a light on fraud. “Ms. Bergman’s efforts and those of her attorneys [Uustal et al.] were critical to our favorable resolution of this case.”
Read full article on whistleblower.org, here.